Gliflozins, the sodium-glucose cotransporter type 2 inhibitors, are primarily antidiabetic drugs whose benefits have been demonstrated in many cardiovascular diseases. They are among the few new drugs that have been successfully introduced for the treatment of not only diabetes, but also hypertension and heart failure. The beneficial effects of gliflozins were first demonstrated in large clinical trials in diabetic patiens 10 years ago. Moreover, their potential was further extended to non-diabetic patients, showing both cardioprotective and nephroprotective effects. Their effects are multifactorial, based primarily on the promotion of glucose and sodium excretion but reaching far beyond. Using experimental models of hypertension, chronic kidney disease and heart failure, we are studying the mechanisms of gliflozin´s action.
Ivana Vaněčková is a head of Laboratory of Experimental hypertension. In the recent years, she has shifted her scientific focus from the renin-angiotensin system and endothelin system to studying gliflozin´s effects in animal models under non-diabetic conditions.